Morepen Laboratories Limited has informed the Exchange regarding a press release dated May 27, 2026, titled "Morepen Labs Q4 Net Profit Rises 69%; CDMO Program Moves into Commercial Execution; Board Proposes a Dividend of 10% to the shareholders for FY26.".
MOREPENLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Morepen Laboratories reported a strong Q4 FY26 with net profit up 69% YoY to Rs. 20 crore and gross revenue up 22% YoY to Rs. 472 crore. The API business grew 17% while Medical Devices surged 31% during the quarter. For the full year FY26, standalone gross revenue crossed Rs. 1,700 crore, up 8% YoY. The company commenced commercial production under its Rs. 825 crore (USD 91 million) global CDMO mandate received from a leading multinational, marking a shift toward long-duration manufacturing partnerships. EBITDA stood at Rs. 32 crore vs Rs. 33 crore in Q4 FY25, reflecting near-term investments in capacity expansion (from ~500 KL to ~800 KL) and Medical Devices growth. The board proposed a 10% dividend for FY26. The company also completed a pivotal bioequivalence study for Resmetirom 100 mg and passed its 4th consecutive USFDA inspection with zero 483 observations.
Strong Q4 profit growth and a new commercial CDMO program signal positive momentum. The near-term EBITDA compression from investment spending is expected to yield operating leverage and margin expansion going forward. The dividend proposal adds a positive signal for shareholders.